Epigenetics Drugs & Diagnostic Technologies Market, By Type (Epigenetic Drugs (DNMT Inhibitors (Azacitidine, Decitabine), HDAC Inhibitors (Vorinostat, Romidepsin)), Epigenetics Diagnostic Technologies (DNA Methylation, ChIP Technology)), and By Region (No

Epigenetics Drugs & Diagnostic Technologies Market, By Type (Epigenetic Drugs (DNMT Inhibitors (Azacitidine, Decitabine), HDAC Inhibitors (Vorinostat, Romidepsin)), Epigenetics Diagnostic Technologies (DNA Methylation, ChIP Technology)), and By Region (North America, Latin America, Europe, Asia Pacific, Middle East & Africa) - Size, Share, Outlook, and Opportunity Analysis, 2022 - 2028

Epigenetic is the study of chemical modifications of some specific genes of an organism. Epigenetic drugs are used to reverse the abnormal gene expression which leads to different types of disease such as cancer, heart disease, diabetes, and mental illnesses. Increasing prevalence of cancer, increasing research and development for new drug molecule along with increasing investment in biotechnology industry is expected to propel the market growth during the forecasted period.
Key features of the study:
This report provides in-depth analysis of the Global Epigenetic Drugs and Diagnostic Technologies market and provides market size (US$ million) and compound annual growth rate (CAGR %) for the forecast period (2022-2028), considering 2021 as the base year
It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategy adopted by key players
It profiles key players in the Global Epigenetic Drugs and Diagnostic Technologies market based on the following parameters – company overview, financial performance, product portfolio, market presence, distribution strategies, key developments, strategies, and future plans
Key companies covered as a part of this study include, 4SC AG, Acetylon Pharmaceuticals, Inc., Astex Pharmaceuticals Inc., CellCentric Ltd., Celleron Therapeutics Ltd., Celgene Corporation, Chroma Therapeutics Ltd., Epigentek Group Inc., Eisai Co. Ltd., EnVivo Pharmaceuticals Inc., Base Genomics, and Oryzon Genomics, S.A.
Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, technology up-gradation, market expansion, and marketing tactics
The Global Epigenetic Drugs and Diagnostic Technologies market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the Global Epigenetic Drugs and Diagnostic Technologies market
Detailed Segmentation:
Global Epigenetic Drugs and Diagnostic Technologies Market, By Type:
Epigenetic Drugs
DNMT Inhibitors
Azacitidine
Decitabine
HDAC Inhibitors
Vorinostat
Romidepsin
Epigenetics Diagnostic Technologies
DNA Methylation
ChIP Technology
Global Epigenetic Drugs and Diagnostic Technologies Market, By Region:
North America
By Type:
Epigenetic Drugs
DNMT Inhibitors
Azacitidine
Decitabine
HDAC Inhibitors
Vorinostat
Romidepsin
Epigenetics Diagnostic Technologies
DNA Methylation
ChIP Technology
By Country
U.S.
Canada
Latin America
By Type:
Epigenetic Drugs
DNMT Inhibitors
Azacitidine
Decitabine
HDAC Inhibitors
Vorinostat
Romidepsin
Epigenetics Diagnostic Technologies
DNA Methylation
ChIP Technology
By Country
Brazil
Mexico
Argentina
Rest of Latin America
Europe
By Type:
Epigenetic Drugs
DNMT Inhibitors
Azacitidine
Decitabine
HDAC Inhibitors
Vorinostat
Romidepsin
Epigenetics Diagnostic Technologies
DNA Methylation
ChIP Technology
By Country
U.K.
Germany
France
Spain
Italy
Russia
Rest of Europe
Asia Pacific
By Type:
Epigenetic Drugs
DNMT Inhibitors
Azacitidine
Decitabine
HDAC Inhibitors
Vorinostat
Romidepsin
Epigenetics Diagnostic Technologies
DNA Methylation
ChIP Technology
By Country
China
Japan
India
Australia
South Korea
ASEAN
Rest of Asia Pacific
Middle East
By Type:
Epigenetic Drugs
DNMT Inhibitors
Azacitidine
Decitabine
HDAC Inhibitors
Vorinostat
Romidepsin
Epigenetics Diagnostic Technologies
DNA Methylation
ChIP Technology
By Country
GCC Countries
Israel
Rest of Middle East
Africa
By Type:
Epigenetic Drugs
DNMT Inhibitors
Azacitidine
Decitabine
HDAC Inhibitors
Vorinostat
Romidepsin
Epigenetics Diagnostic Technologies
DNA Methylation
ChIP Technology
By Country
North Africa
Central Africa
South Africa
Company Profiles
4SC AG *
Company Overview
Product Portfolio
Key Highlights
Financial Overview
Strategies
Acetylon Pharmaceuticals, Inc.
Astex Pharmaceuticals Inc.
CellCentric Ltd.
Celleron Therapeutics Ltd.
Celgene Corporation
Chroma Therapeutics Ltd.
Epigentek Group Inc.
Eisai Co. Ltd.
EnVivo Pharmaceuticals Inc.
Base Genomics
Oryzon Genomics, S.A.
“*” marked represents similar segmentation in other categories in the respective section.